Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
两项 III 期临床试验评估了巴瑞替尼治疗重度斑秃成人患者的安全性,中位随访时间为 2.3 年,最长随访时间达 4 年。
期刊:American Journal of Clinical Dermatology
影响因子:8.8
doi:10.1007/s40257-025-00932-0
King, Brett; Mostaghimi, Arash; Shimomura, Yutaka; Piraccini, Bianca Maria; Blume-Peytavi, Ulrike; Sontag, Angelina; Dutronc, Yves; Denning, Karen; Kolodsick, Jill; Lu, Xiaoyu; Srivastava, Ayush; Sinclair, Rodney